Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment
about
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.Normative comparisons for large neuropsychological test batteries: User-friendly and sensitive solutions to minimize familywise false positives.Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.
P2860
Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Neurocognitive function in HIV ...... o methods to define impairment
@ast
Neurocognitive function in HIV ...... o methods to define impairment
@en
type
label
Neurocognitive function in HIV ...... o methods to define impairment
@ast
Neurocognitive function in HIV ...... o methods to define impairment
@en
prefLabel
Neurocognitive function in HIV ...... o methods to define impairment
@ast
Neurocognitive function in HIV ...... o methods to define impairment
@en
P2093
P2860
P1433
P1476
Neurocognitive function in HIV ...... o methods to define impairment
@en
P2093
Alan Winston
Alejandro Arenas-Pinto
Alex Accoroni
David Dunn
Jonathan Ainsworth
Nicholas I Paton
PIVOT Trial Team
Rebecca Wiggins
Say Pheng Quah
P2860
P304
P356
10.1371/JOURNAL.PONE.0103498
P407
P577
2014-07-31T00:00:00Z